Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | WNT3 | P56703 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL445248 | 0.98 | LMNA (0.34) | LMNAVCPALDH1A1CYP1A2HPGD | |
| Hydrochloric Acid SCHEMBL562710 | 0.98 | LMNA (0.34) | LMNAVCPALDH1A1CYP1A2HPGD | |
| SCHEMBL27627029 | 0.94 | EPHX1 (0.34) | LMNAVCPALDH1A1HPGDCYP2C19 | |
| Trifluoroacetic Acid SCHEMBL30949078 | 0.91 | F11 (0.34) | LMNAVCPBACE1BACE2TTR | |
| SCHEMBL15935489 | 0.88 | LMNA (0.33) | LMNAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL12092098 | 0.84 | LMNA (0.47) | LMNAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL16072051 | 0.82 | SMN1; SMN2 (0.37) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL744123 | 0.82 | SMN1; SMN2 (0.37) | ALDH1A1CYP1A2HPGDCYP2C19BLM | |
| SCHEMBL12020688 | 0.82 | LMNA (0.33) | LMNAALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL20496782 | 0.82 | TTR (0.37) | LMNAALDH1A1HPGDCYP2C19WNT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 643 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228365-A1 | LIPOSOME COMPOSITION FOR CANCER TREATMENT | MASHHAD UNIVERSITY OF MEDICAL SCEINCE (IR) | 2016-08-11 | — | — | US | claimed |
| US-20150306244-A1 | Anthracycline-Antibody Conjugates for Cancer Therapy | IMMUNOMEDICS, INC. | 2015-10-29 | — | — | US | claimed |
| US-8895013-B2 | Anthracycline-antibody conjugates for cancer therapy | IMMUNOMEDICS, INC. (US) | 2014-11-25 | — | — | US | claimed |
| US-20140154273-A1 | Anthracycline-Antibody Conjugates for Cancer Therapy | IMMUNOMEDICS, INC. (US) | 2014-06-05 | — | — | US | claimed |
| US-8568729-B2 | Anthracycline-antibody conjugates for cancer therapy | IMMUNOMEDICS, INC. (US) | 2013-10-29 | — | — | US | claimed |
| US-20130171176-A1 | Anthracycline-Antibody Conjugates for Cancer Therapy | IMMUNOMEDICS, INC. (US) | 2013-07-04 | — | — | US | claimed |
| US-8361464-B2 | Anthracycline-Antibody Conjugates for Cancer Therapy | IMMUNOMEDICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| JP-4805137-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-09-22 | — | — | US | claimed |
| EP-2315771-A2 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | Sloan Kettering Institute For Cancer Research (US) | 2011-05-04 | — | — | EP | claimed |
| US-20040202666-A1 | Anti-cancer anthracycline drug-antibody conjugates | IMMUNOMEDICS, INC. | 2004-10-14 | — | — | US | claimed |
| WO-2004067038-A1 | ANTHRACYCLINE-ANTIBODY CONJUGATES | IMMUNOMEDICS, INC. (US) | 2004-08-12 | — | — | WO | claimed |
| WO-2004032971-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | claimed |
| EP-0752102-B1 | IMMUNOENZYMATIC CONJUGATE, PREPARATION METHOD THEREFOR AND USES THEREOF | PASTEUR SANOFI DIAGNOSTICS (FR) | 2000-11-15 | — | — | EP | claimed |
| US-6027874-A | IMMUNOASSAY BY CONTACTING SAMPLE WITH CONJUGATE OF GLYCOSYLATED LABELING ENZYMES AND IMMUNOLOGICAL SUBSTANCE, AND DETECTING COMPLEX FORMED; FOR INCREASED SENSITIVITY OF VIRAL INFECTIONS | PASTEUR SANOFI DIAGNOSTICS (FR) | 2000-02-22 | — | — | US | claimed |
| EP-0752102-A1 | IMMUNOENZYMATIC CONJUGATE, PREPARATION METHOD THEREFOR AND USES THEREOF | PASTEUR SANOFI DIAGNOSTICS (FR) | 1997-01-08 | — | — | EP | claimed |
| EP-0751959-A1 | MODIFIED POLYPEPTIDES WITH INCREASED BIOLOGICAL ACTIVITY | NEW ENGLAND DEACONESS HOSPITAL (US) | 1997-01-08 | — | — | EP | claimed |
| WO-1996023226-A9 | IMMUNOENZYMATIC CONJUGATE, PREPARATION METHOD THEREFOR AND USES THEREOF | — | 1996-10-31 | — | — | WO | claimed |
| WO-1996023226-A1 | IMMUNOENZYMATIC CONJUGATE, PREPARATION METHOD THEREFOR AND USES THEREOF | PASTEUR SANOFI DIAGNOSTICS (FR) | 1996-08-01 | — | — | WO | claimed |
| WO-1995025746-A1 | MODIFIED POLYPEPTIDES WITH INCREASED BIOLOGICAL ACTIVITY | NEW ENGLAND DEACONESS HOSPITAL (US) | 1995-09-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040202666-A1 | Anti-cancer anthracycline drug-antibody conjugates | BCR, TOP2A, ABCB1 | LMNA 3892/4885VCP 3587/4885ALDH1A1 558/4885 |
| US-20150306244-A1 | Anthracycline-Antibody Conjugates for Cancer Therapy | BCR, TOP2A, DNAH12 | LMNA 4264/4885VCP 3878/4885ALDH1A1 309/4885 |
| US-20140154273-A1 | Anthracycline-Antibody Conjugates for Cancer Therapy | BCR, TOP2A, DNAH12 | LMNA 4264/4885VCP 3878/4885ALDH1A1 309/4885 |
| US-20130171176-A1 | Anthracycline-Antibody Conjugates for Cancer Therapy | BCR, TOP2A, DNAH12 | LMNA 4264/4885VCP 3878/4885ALDH1A1 309/4885 |
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | B3GAT3, MICA, SIGLEC7 | LMNA 4097/4885VCP 2180/4885ALDH1A1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.